SG11201805872SA - Chimeric antigen receptors targeting epidermal growth factor receptor variant iii - Google Patents

Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Info

Publication number
SG11201805872SA
SG11201805872SA SG11201805872SA SG11201805872SA SG11201805872SA SG 11201805872S A SG11201805872S A SG 11201805872SA SG 11201805872S A SG11201805872S A SG 11201805872SA SG 11201805872S A SG11201805872S A SG 11201805872SA SG 11201805872S A SG11201805872S A SG 11201805872SA
Authority
SG
Singapore
Prior art keywords
international
rule
factor receptor
epidermal growth
chimeric antigen
Prior art date
Application number
SG11201805872SA
Inventor
Oi Kwan Wong
Joyce Ching Chou
Mathilde Brunnhilde DUSSEAUX
Julianne Smith
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG11201805872SA publication Critical patent/SG11201805872SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 1111111101111011101010111110101111101110111011110111111111101111101111011111 International Bureau ... ..51 jd (10) International Publication Number ..... ..... ..r .,,,i (43) International Publication Date WO 2017/125830 Al 27 July 2017 (27.07.2017) WIPO I PCT (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, C07K 14/47 (2006.01) C07K 16/28 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, A61K 38/00 (2006.01) C07K 16/30 (2006.01) KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, A61K 48/00 (2006.01) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (21) International Application Number: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, PCT/IB2017/050108 TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, (22) International Filing Date: ZA, ZM, ZW. 10 January 2017 (10.01.2017) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (26) Publication Language: English TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, (30) Priority Data: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, 62/281,533 21 January 2016 (21.01.2016) US DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 62/431,758 8 December 2016 (08.12.2016) US LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GW, KM, ML, MR, NE, SN, TD, TG). New York, NY 10017 (US). Declarations under Rule 4.17: (72) Inventors: WONG, Oi Kwan; 15 Arroyo View Circle, — as to the identity of the inventor (Rule 4.17(i)) Belmont, CA 94002 (US). CHOU, Joyce Ching; 767 — Silkoak Way, Sunnyvale, CA 94086 (US). DUSSEAUX, — as to applicant's entitlement to apply for and be granted a — Mathilde Brunnhilde; 19 domaine de Chateau, _ Gaillard, patent (Rule 4.17(ii)) 1675 as to the applicant's entitlement to claim the priority of the = 94700 Maisons-Alfort (FR). SMITH, Julianne; application (Rule 4.17(iii)) York Avenue, New York (US). , NY 10128 —earlier East 42nd Published: (74) Agent: WALDRON, Roy F.; Pfizer Inc., 235 Street, MS 235/9/S20, New York, NY 10017 = (US). — with international search report (Art. 21(3)) for every (81) Designated States (unless otherwise indicated, kind AE, AG, AL, AM, with sequence listing part of description (Rule 5.2(a)) of national protection available): AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, DJ, DK, DM, = BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, = = = = = TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III (54) Title: CHIMERIC ANTIGEN RECEPTORS = 'IA HG. loo 80 - N. M F98 (EGFR Negative) 1-1 60 40 en 20 GO ir) 0 I -7) „..,. n F98 -EGFRwt Ei F98 -EGFRvill ell 0 10 2 10 3 10 4 10 5 - IN 1-1 (57) : The invention provides Chimeric Antigen Receptors (CARs) that specifically bind to EGFRv111 (Epidermal Growth N Factor Receptor Variant III). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nude - ic acids, and methods of making thereof, engineered immune cells, and nucleic acids. The invention further relates to therapeutic C methods for using these CARs and engineered immune cells for the treatment of EGFRv111-mediated pathologies, including cancers such as glioblastoma.
SG11201805872SA 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii SG11201805872SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662281533P 2016-01-21 2016-01-21
US201662431758P 2016-12-08 2016-12-08
PCT/IB2017/050108 WO2017125830A1 (en) 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Publications (1)

Publication Number Publication Date
SG11201805872SA true SG11201805872SA (en) 2018-08-30

Family

ID=57868301

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202111458RA SG10202111458RA (en) 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
SG11201805872SA SG11201805872SA (en) 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202111458RA SG10202111458RA (en) 2016-01-21 2017-01-10 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii

Country Status (22)

Country Link
US (3) US10259876B2 (en)
EP (1) EP3405481B1 (en)
JP (2) JP6823659B2 (en)
KR (1) KR102479606B1 (en)
CN (1) CN108699124A (en)
AU (1) AU2017208834B2 (en)
BR (1) BR112018014585A2 (en)
CA (1) CA2954014A1 (en)
DK (1) DK3405481T3 (en)
EA (1) EA201891641A1 (en)
ES (1) ES2942362T3 (en)
IL (1) IL260666B2 (en)
MX (1) MX2018008978A (en)
MY (1) MY192474A (en)
NZ (1) NZ744821A (en)
PH (1) PH12018501473A1 (en)
RU (1) RU2751662C2 (en)
SA (1) SA518392058B1 (en)
SG (2) SG10202111458RA (en)
TW (2) TWI755547B (en)
UA (1) UA125252C2 (en)
WO (1) WO2017125830A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA43135A (en) 2015-10-30 2018-09-05 Aleta Biotherapeutics Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER
KR20180083868A (en) 2015-10-30 2018-07-23 알레타 바이오쎄라퓨틱스, 인크. Composition and method for tumor transduction
TWI755547B (en) 2016-01-21 2022-02-21 美商輝瑞股份有限公司 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
ES2904593T3 (en) 2016-01-21 2022-04-05 Pfizer Monospecific and bispecific antibodies to epidermal growth factor receptor variant III and CD3 and their uses
US11590167B2 (en) 2016-12-03 2023-02-28 Juno Therapeutic, Inc. Methods and compositions for use of therapeutic T cells in combination with kinase inhibitors
JP2020522489A (en) 2017-06-02 2020-07-30 ジュノー セラピューティクス インコーポレイテッド Articles of manufacture and methods for treatment with adoptive cell therapy
WO2019195586A1 (en) * 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
AU2019312411A1 (en) * 2018-07-26 2021-01-07 Legend Biotech Ireland Limited Nef-containing T cells and methods of producing thereof
CN109265561B (en) * 2018-09-25 2021-05-25 山东兴瑞生物科技有限公司 anti-EGFRv III safe chimeric antigen receptor, preparation method thereof, NK cell modified by same and application
JP2022513076A (en) * 2018-11-19 2022-02-07 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Modular polycistronic vector for CAR and TCR transduction
AU2019386063A1 (en) * 2018-12-01 2021-07-01 Allogene Therapeutics, Inc. Chimeric antigen receptors targeting B-cell maturation antigen and methods of use thereof
CN113621062A (en) * 2018-12-21 2021-11-09 豪夫迈·罗氏有限公司 Antibodies that bind to CD3
CN111454358A (en) * 2019-01-18 2020-07-28 四川科伦博泰生物医药股份有限公司 Chimeric antigen receptor and application thereof
EP3938387A1 (en) * 2019-03-15 2022-01-19 The United States of America, as represented by the Secretary, Department of Health and Human Services Chimeric adaptor and kinase signaling proteins and their use in immunotherapy
CA3142833A1 (en) * 2019-07-02 2021-01-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Monoclonal antibodies that bind egfrviii and their use
WO2021022044A1 (en) * 2019-07-31 2021-02-04 Forty Seven, Inc. Depletion regimes for engineered t-cell or nk-cell therapy
CN111019959B (en) * 2019-12-30 2022-09-13 北京立康生命科技有限公司 Nucleotide molecule for in vitro transcription of mRNA, presenting cell and application
US20230147832A1 (en) * 2020-01-22 2023-05-11 City Of Hope Oncolytic virus compositions including il-15 complex and methods for the treatment of cancer
KR20230122618A (en) 2020-12-21 2023-08-22 알로젠 테라퓨틱스 인코포레이티드 Protease Activated CD45-Gated CAR
MX2023008809A (en) 2021-01-29 2023-08-04 Allogene Therapeutics Inc KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, ß2m, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS.
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
WO2024027835A1 (en) * 2022-08-05 2024-02-08 北京鼎成肽源生物技术有限公司 Antibody targeting egfrviii and use thereof in cell immunotherapy
CN116284435A (en) * 2022-09-19 2023-06-23 卡瑞济(北京)生命科技有限公司 EGFRvIII chimeric antigen receptor and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0564531T3 (en) 1990-12-03 1998-09-28 Genentech Inc Enrichment procedure for variant proteins with altered binding properties
CA2137558A1 (en) 1992-07-17 1994-02-03 Wayne A. Marasco Method of intracellular binding of target molecules
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
AU2001243288B2 (en) 2000-02-24 2005-11-24 Life Technologies Corporation Simultaneous stimulation and concentration of cells
AU2001239857B9 (en) * 2000-02-25 2006-07-27 Duke University Anti-EGFRvIII SCFVS with improved cytotoxicity and yield, immunotoxins based thereon, and methods of use thereof
US20100105136A1 (en) 2006-10-09 2010-04-29 The General Hospital Corporation Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
SG189482A1 (en) 2010-10-27 2013-05-31 Cellectis Method for increasing the efficiency of double-strand break-induced mutagenesis
US9249217B2 (en) 2010-12-03 2016-02-02 Secretary, DHHS Bispecific EGFRvIII x CD3 antibody engaging molecules
PL3214091T3 (en) * 2010-12-09 2019-03-29 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
SI2694549T1 (en) 2011-04-08 2018-12-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
US20150017136A1 (en) 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
JP6154895B2 (en) 2012-06-07 2017-06-28 デューク ユニバーシティー Human bispecific EGFRvIII antibody binding molecule
CN104583230A (en) * 2012-07-13 2015-04-29 宾夕法尼亚大学董事会 Enhancing activity of CAR T cells by co-introducing a bispecific antibody
ES2714523T3 (en) 2012-09-04 2019-05-28 Cellectis Chimeric receptor of multi-chain antigens and uses thereof
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
DK2958943T3 (en) * 2013-02-20 2019-12-09 Univ Pennsylvania Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
DK2968552T3 (en) 2013-03-14 2020-04-14 Scripps Research Inst TARGETING ANTIBODY CONJUGATES AND APPLICATIONS THEREOF
CA2912375C (en) 2013-05-13 2023-03-14 Cellectis Methods for engineering highly active t cell for immunotherapy
FI2997141T3 (en) 2013-05-13 2022-12-15 Cd19 specific chimeric antigen receptor and uses thereof
CA2913830C (en) 2013-05-29 2021-06-29 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
WO2015006482A1 (en) 2013-07-09 2015-01-15 Duke University CERTAIN IMPROVED HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
CA2920173C (en) 2013-08-07 2021-08-10 Affimed Therapeutics Ag Antibody binding sites specific for egfrviii
EP3808410A1 (en) * 2013-12-20 2021-04-21 Cellectis Method of engineering multi-input signal sensitive t cell for immunotherapy
KR20180125632A (en) 2014-07-29 2018-11-23 화이자 인코포레이티드 EGFRvIII SPECIFIC CHIMERIC ANTIGEN RECEPTORS FOR CANCER IMMUNOTHERAPY
TWI744242B (en) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Antibody constructs for egfrviii and cd3
TWI755547B (en) 2016-01-21 2022-02-21 美商輝瑞股份有限公司 Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
ES2904593T3 (en) 2016-01-21 2022-04-05 Pfizer Monospecific and bispecific antibodies to epidermal growth factor receptor variant III and CD3 and their uses

Also Published As

Publication number Publication date
TWI755547B (en) 2022-02-21
IL260666B (en) 2022-10-01
US20220227874A1 (en) 2022-07-21
WO2017125830A1 (en) 2017-07-27
IL260666A (en) 2018-09-20
MY192474A (en) 2022-08-23
JP2021036873A (en) 2021-03-11
BR112018014585A2 (en) 2018-12-11
RU2018130088A (en) 2020-02-25
JP7198797B2 (en) 2023-01-04
CN108699124A (en) 2018-10-23
EP3405481A1 (en) 2018-11-28
EA201891641A1 (en) 2019-01-31
JP6823659B2 (en) 2021-02-03
US20190144550A1 (en) 2019-05-16
US20170210811A1 (en) 2017-07-27
JP2019506394A (en) 2019-03-07
US10259876B2 (en) 2019-04-16
MX2018008978A (en) 2019-01-10
TW201920237A (en) 2019-06-01
EP3405481B1 (en) 2023-01-18
AU2017208834A1 (en) 2018-08-09
PH12018501473A1 (en) 2019-03-11
DK3405481T3 (en) 2023-04-17
UA125252C2 (en) 2022-02-09
TW201734038A (en) 2017-10-01
SA518392058B1 (en) 2023-02-12
TWI634125B (en) 2018-09-01
CA2954014A1 (en) 2017-07-21
AU2017208834B2 (en) 2021-09-02
RU2751662C2 (en) 2021-07-15
RU2018130088A3 (en) 2020-07-29
SG10202111458RA (en) 2021-11-29
NZ744821A (en) 2023-06-30
ES2942362T3 (en) 2023-05-31
KR20180099890A (en) 2018-09-05
IL260666B2 (en) 2023-02-01
KR102479606B1 (en) 2022-12-21
US11267892B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
SG11201805872SA (en) Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
SG11201807489PA (en) Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201907580SA (en) Combination therapies for treatment of bcma-related cancers and autoimmune disorders
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201900468YA (en) Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof
SG11201908023YA (en) T cell receptors and immune therapy using the same against prame positive cancers
SG11201905812WA (en) Azolopyrimidine for the treatment of cancer-related disorders
SG11201804038VA (en) Conditionally active heterodimeric polypeptides and methods of use thereof
SG11201901126UA (en) Combination therapy for cancer
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201805044WA (en) Compounds useful as kinase inhibitors
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201908598PA (en) Compounds useful in the treatment or prevention of a prmt5-mediated disorder
SG11201808125RA (en) Methods for solid tumor treatment
SG11201909963YA (en) Methods for treating dravet syndrome
SG11201811292RA (en) Compositions and methods for the depletion of cells
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201807827VA (en) Process for the preparation of pegylated drug-linkers and intermediates thereof
SG11201806121PA (en) Ror2 antibody compositions and related methods
SG11201805755SA (en) Methods of administering hepcidin
SG11201900361RA (en) Methods of treating prostate cancer